Infectious Disease

The COVID-19 immune response appears to be strong in cancer patients

HealthDay News – According to a research letter published online Aug. 11 in JAMA Oncology, the seropositivity rate in cancer patients remains high four months after the second dose of the COVID-19 vaccine.

Noa Eliakim-Raz, MD, of Rabin Medical Center in Petah Tikva, Israel, and colleagues studied the antispike (anti-S) immunoglobulin (Ig) G antibody response to the messenger RNA vaccine (BioNTech-Pfizer) in 95 cancer patients versus 66 controls about four months after the second dose of vaccine.

The researchers found that a median of 123 days after the second vaccination, 87 percent of the patients and 100 percent of the controls were seropositive for anti-S-IgG antibodies. In cancer patients, the mean titer values ​​were significantly lower than in the control group (417 versus 1,220 arbitrary units per milliliter). The median IgG titers varied by 3.6-fold depending on the tumor type and 8.8-fold depending on the type of cancer treatment, the lowest titers being observed with immunotherapy plus chemotherapy and biological therapy.

Continue reading

“Long-term cellular memory could question the need for a third BNT162b2 booster dose,” the authors write.

One author revealed financial ties to the pharmaceutical industry.

Summary / full text (subscription or payment may be required)


Cancer COVID19 COVID19 Vaccines Oncology

Related Articles